Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open, Single-arm Phase IIb Clinical Study to Evaluate the Safety and Efficacy of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis

NCT06976177 is registered in ClinicalTrials.gov with Shaanxi Micot Pharmaceutical Technology Co., Ltd. as lead sponsor.

NCT NCT06976177
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06976177 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open, Single-arm Phase IIb Clinical Study to Evaluate the Safety and Efficacy of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis
Lead sponsor
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
June 7, 2024
Completion date
December 12, 2025
Enrollment
310 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

secondary hyperparathyroidism (shpt) in subjects with chronic kidney disease (ckd) on hemodialysis